

Precis:

Patients with metastatic melanoma who are HLA-A2 positive and hepatitis B negative and HIV negative will be immunized with a recombinant vaccinia virus encoding the MART-1 melanoma antigen. This study will evaluate the toxicity, immunologic effects and potential therapeutic role of this immunization alone or in conjunction with the administration of interleukin-2.